The Wall Street Journal
BUSINESS
By ALAN MURRAY
Drug Makers' Politics Produces a Bitter Pill
November 15, 2006; Page A2
Since Election Day, drug stocks have gotten clobbered. Pfizer, Wyeth, Eli Lilly and Novartis have tumbled 5% or more; GlaxoSmithKline, Merck and Johnson & Johnson are down 4% or more; and Bristol-Myers Squibb is down 3.5%. Add it up, and you've got nearly $50 billion in market value wiped out by Democratic victories.
That's the price big pharma is paying for a badly bungled political strategy. For years, the industry operated on the assumption it could get what it wanted out of Washington. Then, when the going got tough, it doubled down on Republicans and ignored a groundswell of public anger over high drug prices. Even ex-congressman Billy Tauzin, the Democrat-turned-Republican who heads the industry's trade group, acknowledges that before he took over two years ago, the group used "a scorched-earth policy" to get its way.
The most conspicuous example of overreach was a line inserted in the Medicare Modernization Act of 2003 that prohibited the U.S. government from negotiating prices directly with drug companies. That prohibition was unnecessary; the law created a structure in which private insurers and health plans did the negotiating on the government's behalf. But someone allied with the drug industry -- it's still a little unclear who -- insisted on making the implicit explicit, and in the process, created a campaign issue for Democrats.
(snip)
Truth is, drug companies can't really "negotiate" with the government, any more than a backwoods hiker can negotiate with a 900-pound grizzly bear. With a market share of about 46%, the government would set drug prices, not negotiate them, and then establish "formularies" telling seniors which drugs they could use and which ones they couldn't. Would that make seniors feel better off? I doubt it.
(snip)
URL for this article:
http://online.wsj.com/article/SB116355141789823288.html (subscription)